Stock screenerAll disclosures →
EDGAR →
CRL
Conviction 100HealthcareScan · Thu, Sep 24, 2026Charles River Laboratories International, Inc. (CRL) closed at $294.51 (+6.19%) on Sep 24, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 61, RS Rating 96, -1.4% from its 52-week high, +45.5% year to date. Sector: Healthcare · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH.
CRL$294.51+6.19%
ResistanceSupportVol 14Insider sellCongress buyCongress sell2
10
Vol MA14 1.14M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCHwww.criver.com ↗
Price294.51
Change+6.19%
Gap+0.68%
Rel volume2.94×
Avg volume1.03M
Avg $ vol290.79M
SMA 20282.88
SMA 50267.77
SMA 200206.96
Price vs 50+9.99%
Price vs 200+42.30%
MA stackbullish
50/200 cross—
Supertrendup · 269.54
RSI (14)61
MACD hist-0.56
MACD cross—
Stoch %K / %D87 / 62
ADX (14)25
+DI / −DI25 / 12
RSI divergence—
MACD divergence—
ATR %3.55%
ADR %3.16%
52w high298.58
52w low145.57
From 52w high-1.36%
Above 52w low+102.32%
New 52w highNo
SqueezeOff
Bollinger width10.71%
%B0.88
Donchian pos75.59%
Donchian high303.31
Donchian low267.27
AVWAP (52w high)283.04
vs AVWAP high+4.05%
AVWAP (52w low)198.96
vs AVWAP low+48.02%
OBV trendFlat
Chaikin MF (20)-0.08
Today vs 20d2.94×
Avg vol (14d)1.14M
Avg vol (20d)1.03M
Avg $ vol (20d)290.79M
Market cap14.06B
RS Rating96 / 99
RS 3m (vs SPY)+33.96%
RS 6m (vs SPY)+60.72%
RS line new highNo
Trend template8/8
Technical rank91.3
1 week+4.56%
1 month-1.05%
3 months+38.46%
6 months+77.53%
1 year+96.01%
YTD+45.49%
P/E-97.41
P/B4.95
P/S3.50
P/FCF27.12
EPS-2.91
Div yield—
ROE-5.08%
ROA-1.92%
Debt/Eq0.57
Current1.35
EV/EBITDA36.17
Gross margin7.47%
Net margin-3.59%
Rev growth-0.85%
EPS growth-750.08%
Price target292.38
Target upside-0.72%
Analyst ratingBuy
Institutional132.88%
Ent. value15.5B
Revenue1B
Net income-1.48M
Gross profit—
Free cash flow518.49M
IndustrySERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
ExchangeNYSE
Shares out48.17M
Employees19.7K
ListedFri, Jun 23, 2000
Free float48.7M
Float %98.7%
Short interest2.54M
Days to cover2.8d
Short volume62.2%
Squeeze score54 / 100
Next earnings—
EPS forecast—
Last EPS vs est$3.02 vs $2.72
Last surprise+11.0% beat
Setup gradeA+
Conviction100 / 100
Pattern quality—
Tech rank91.3 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance301.31
Support271.96
Days since event—
Candle confirm—
Financials as of Sat, Jun 27, 2026 · quarterly.
Recent news
- Contract Research Organization Services Market Forecasts Growth from $107.03B (2025) to $180.56B by 2030, Profiling IQVIA, Charles River, Syneos Health & WuXi AppTecYahoo Finance · Thu, Sep 24, 2026
- Drug Safety Market Forecasts Growth from $7.12B (2026) to $10.21B by 2032, Profiling IQVIA, ICON, Charles River, Oracle & ParexelYahoo Finance · Thu, Sep 24, 2026
- Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor DayYahoo Finance · Thu, Sep 24, 2026
- Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue waveYahoo Finance · Thu, Sep 24, 2026
- Capitalize on Pharmacokinetics Outsourcing Disruption as Charles River, Labcorp, WuXi AppTec, Eurofins and Sygnature Compete to Dominate Drug Development ROIYahoo Finance · Wed, Sep 23, 2026
- Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Redraw Global Market ShareYahoo Finance · Wed, Sep 23, 2026
- Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D ROI and Outsmart the Global MarketYahoo Finance · Wed, Sep 23, 2026
- Capitalize on the Toxicology Testing Services Market Shift: Benchmark Labcorp, Charles River, Eurofins, SGS and WuXi AppTec to Secure Growth and Outpace DisruptionYahoo Finance · Wed, Sep 23, 2026
- Disrupt Drug Discovery and Secure R&D ROI: Benchmark Fragment-Based Strategies from Astex, Evotec, Charles River, Schrödinger and Vernalis Through 2030Yahoo Finance · Tue, Sep 22, 2026
- Capitalize on the Global PDX Models Shift: Benchmark Charles River, Crown Bioscience, Champions Oncology, The Jackson Laboratory and Oncodesign to Secure Precision Oncology ROIYahoo Finance · Tue, Sep 22, 2026
Congress activity
Disclosed STOCK Act trades in CRL · 5 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Jefferson Shreve house · R · IN · traded 2025-05-12 | Sell | $15K–$50K | 2025-05-12 | 2025-06-22 | |
Jefferson Shreve house · R · IN · traded 2025-05-08 | Buy | $15K–$50K | 2025-05-08 | 2025-06-22 | |
 Rob Bresnahan house · PA · traded 2025-05-15 | Sell | $1K–$15K | 2025-05-15 | 2025-05-31 | |
Rob Bresnahan house · PA · traded 2025-04-08 | Buy | $15K–$50K | 2025-04-08 | 2025-05-08 | |
 Julie Johnson house · D · TX · traded 2025-01-15 | Buy | $1K–$15K | 2025-01-15 | 2025-02-12 |
Insider activity
SEC Form 4 transactions in CRL · open-market 3 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
FOSTER JAMES C Director · Common Stock · 2026-08-25 | Exercise | 12.43K | $2.6M | 2026-08-25 | 2026-08-27 |
FOSTER JAMES C Director · Common Stock · 2026-08-25 | Sell | 33.56K | $10M | 2026-08-25 | 2026-08-27 |
FOSTER JAMES C Director · Common Stock · 2026-08-25 | Exercise | 21.13K | $4.1M | 2026-08-25 | 2026-08-27 |
FOSTER JAMES C Director · Stock Options (Right to Buy) · 2026-08-25 | Exercise | 21.13K | — | 2026-08-25 | 2026-08-27 |
FOSTER JAMES C Director · Stock Options (Right to Buy) · 2026-08-25 | Exercise | 12.43K | — | 2026-08-25 | 2026-08-27 |
Parisotto Shannon M CEVP, Disc & Safety Assessment · Common Stock · 2026-08-19 | Sell | 2.04K | $600K | 2026-08-19 | 2026-08-20 |
Parisotto Shannon M CEVP, Disc & Safety Assessment · Common Stock · 2026-08-19 | Exercise | 2.04K | $396K | 2026-08-19 | 2026-08-20 |
Parisotto Shannon M CEVP, Disc & Safety Assessment · Stock Options (Right to Buy) · 2026-08-19 | Exercise | 2.04K | — | 2026-08-19 | 2026-08-20 |
Girshick Birgit Chief Executive Officer · Common Stock · 2026-08-19 | Gift | 528 | — | 2026-08-19 | 2026-08-20 |
Andrews Nancy C Director · Common Stock · 2026-08-18 | Sell | 573 | $163K | 2026-08-18 | 2026-08-20 |
SEC filings
EDGAR filings in CRL · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.